30-day average of 22 articles · scale −100 to +100
Across 22 scored articles from Oct 16 to Nov 14, 2026 (UTC),
the average sentiment of Intuitive Surgical news is Somewhat Bullish (+37)
on a scale from −100 to +100.
That is down 7 points from the previous 30 days (+44).
🌍 Worldwide procedures grew 14%, with international markets up 20%.
📉 U.S. da Vinci procedure growth slowed to 10% in Q3.
Slightly Bullish +20
A $5.9 Billion Fund Is Betting Big on Intuitive Surgical
AI-generated analysis
Key insights
📉 Intuitive Surgical's U.S. da Vinci procedure growth slowed to 10% in Q3, the lowest level since the COVID-19 pandemic.
📈 Worldwide da Vinci procedures grew 14% in Q3, with international markets expanding at a robust 20% rate.
💰 The company placed 546 da Vinci systems in the third quarter, up from 427 placements a year earlier.
✂️ Intuitive plans to reduce instrument and accessory revenue per procedure by 3% to 5% to win high-volume benign surgeries.
📉 Valuation compression has pushed the stock to 37x forward earnings, down from a five-year average of 54x.
📉 The consensus analyst price target fell from $593 to $487 following recent operational and financial data.
💼 GuardCap Asset Management opened a new position in ISRG with 167,863 shares worth $68 million in Q3.
🔭 Analysts expect normalized EPS to grow from $8.93 in 2025 to $14.04 by 2028.
📅 The next major catalyst is the fourth-quarter report expected early next year regarding U.S. growth trends.
📈 Bullish signals
📉Intuitive Surgical achieved a 22% revenue increase and 14% worldwide procedure growth in Q3, driven by strong international expansion.
💰The company successfully placed 546 da Vinci systems in the third quarter, demonstrating continued hospital adoption despite domestic headwinds.
🔭Analysts project normalized earnings per share to rise significantly from $8.93 in 2025 to $14.04 by 2028.
📉 Risk factors
📉U.S. da Vinci procedure growth slowed to 10% in Q3, the lowest rate seen since the COVID-19 pandemic.
✂️The company plans to cut instrument and accessory revenue per procedure by 3% to 5%, which will temporarily reduce revenue per case before volume gains materialize.
📉Valuation compression has driven the stock price down to 37x forward earnings, well below its five-year average of 54x.
Article
Intuitive Surgical (ISRG) recently faced headwinds as U.S. da Vinci procedure growth slowed to 10% in the third quarter, marking its lowest rate since the COVID-19 pandemic. Despite this domestic slowdown, the company reported a 22% revenue increase and 14% worldwide procedure growth, driven by strong international expansion with 20% growth outside the U.S. Additionally, Intuitive successfully placed 546 da Vinci systems in the third quarter, an increase from 427 a year prior.
To capture more high-volume benign surgeries, Intuitive Surgical plans to cut instrument and accessory revenue per procedure by 3% to 5%. This strategic pricing adjustment has caused the stock to trade at 37x forward earnings, significantly below its five-year average of 54x. Consequently, the consensus analyst price target has decreased from $593 a year ago to $487, though this still implies potential upside from recent lows.
GuardCap Asset Management, which oversees $5.9 billion in assets, initiated a new position in Intuitive Surgical during the third quarter, purchasing 167,863 shares worth approximately $68 million. This investment represents 4.7% of GuardCap's U.S. stock holdings and is its largest new or added position for the period. Analysts project normalized earnings per share to rise from $8.93 in 2025 to $14.04 by 2028, suggesting long-term growth potential despite current valuation compression.
The company's next critical test will be its fourth-quarter report early next year, which is expected to provide clarity on U.S. procedure growth trends for 2027. Investors are closely watching whether the domestic slowdown persists or if international momentum can offset any further declines in the core U.S. market.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
Intuitive Surgical (NASDAQ:ISRG) faces a mixed analyst outlook following a cluster of price target reductions from major brokerages on Friday. Citigroup lowered its target from $590 to $500, while BTIG Research, Robert W. Baird, and Sanford C. Bernstein also cut their targets to $469, $500, and $685 respectively, though most maintained 'buy' or 'outperform' ratings. Conversely, HSBC recently decreased its target but kept a buy rating, highlighting a divergence in analyst sentiment regarding the stock's immediate valuation.
The company reported strong quarterly financial results on April 21st, beating consensus estimates with $2.50 EPS and $2.77 billion in revenue, representing a 23% year-over-year increase. The firm achieved a net margin of 28.45% and a return on equity of 17.09%, demonstrating robust profitability despite the recent analyst downgrades. Analysts anticipate an EPS of $8.62 for the current fiscal year, suggesting continued growth expectations persist among the investment community.
Insider trading activity shows mixed signals with executives Gary Loeb and Iman Jeddi selling shares under pre-arranged Rule 10b5-1 plans in June, totaling over $3 million in sales. However, institutional ownership remains high at 83.64%, with significant additions from Regent Peak Wealth Advisors, Hyperion Asset Management, and Northside Capital Management during the second quarter, indicating continued confidence from large capital holders despite recent insider offloading.
📉 Citigroup lowered price target to $500 while maintaining 'buy' rating.
📈 Q1 revenue hit $2.77B, beating estimates with 23% year-over-year growth.
💰 Executives sold shares totaling over $2.5 million under pre-arranged plans.
📊 Institutional investors own 83.64% of outstanding stock as hedge funds buy in.
🔮 Analysts forecast $8.62 EPS for the current fiscal year.
📉 Citigroup reduced its price target for Intuitive Surgical from $590.00 to $500.00 while maintaining a 'buy' rating.
📉 BTIG Research, Robert W. Baird, and Sanford C. Bernstein also lowered their respective price targets on Friday.
📈 The company reported Q1 EPS of $2.50, beating the consensus estimate of $2.08 by $0.42.
💰 Revenue reached $2.77 billion for the quarter, up 23% year-over-year against a consensus of $2.62 billion.
📊 Intuitive Surgical achieved a net margin of 28.45% and a return on equity of 17.09% in the latest quarter.
👔 EVP Gary Loeb sold 400 shares worth $169,656 under a Rule 10b5-1 trading plan on June 10th.
👔 SVP Iman Jeddi sold 5,625 shares worth $2.37 million under a pre-arranged plan on June 1st.
📈 Regent Peak Wealth Advisors increased its stake by 7.2% to own 800 shares valued at $318,000.
📈 Hyperion Asset Management lifted its position by 49.8%, now holding 419,329 shares worth $166.76 million.
📈 Northside Capital Management initiated a new stake valued at $669,000 during the second quarter.
🏦 Institutional investors and hedge funds own 83.64% of the company's outstanding stock.
🔮 Analysts anticipate Intuitive Surgical will post $8.62 EPS for the current fiscal year.
Bullish Signals
Revenue beat estimates by $150 million at $2.77 billion.
Net margin reached 28.45% with strong operational efficiency.
Quarterly revenue grew 23% year-over-year.
Institutional holdings increased nearly 50% in Q2.
Analysts anticipate EPS of $8.62 for the fiscal year.
Risk Factors
Citigroup cut target to $500 from $590 due to valuation concerns.
Multiple analysts including BTIG, Baird, and Bernstein recently lowered targets.
Executives Loeb and Jeddi sold over $3 million in June shares.
Bullish Signals
Intuitive Surgical reported revenue of $2.77 billion, which beat the consensus estimate of $2.62 billion by $150 million.
The company achieved a net margin of 28.45% and a return on equity of 17.09%, indicating strong operational efficiency.
Quarterly revenue grew 23% year-over-year, demonstrating sustained demand for the da Vinci surgical systems.
Major institutional investors like Hyperion Asset Management increased their holdings by nearly 50% in the second quarter.
Analysts anticipate an EPS of $8.62 for the current fiscal year, reflecting continued growth expectations.
Despite recent insider sales, a significant majority of shares (83.64%) are held by institutional investors and hedge funds.
Risk Factors
Citigroup reduced its price target from $590 to $500, citing potential valuation concerns despite maintaining a buy rating.
Multiple other analysts including BTIG Research, Robert W. Baird, and Sanford C. Bernstein recently lowered their price targets.
Executives Gary Loeb and Iman Jeddi sold a combined total of over $3 million in shares during June under pre-arranged plans.
Intuitive Surgical (NASDAQ:ISRG) shares experienced a significant gap down, opening at $365.03 after closing the previous session at $402.33. This decline was primarily triggered by JPMorgan Chase lowering its price target from $550.00 to $450.00, despite maintaining an overweight rating on the stock. The immediate market reaction saw shares trade around $355.92 with elevated volume of 2.26 million shares.
The broader analyst sentiment surrounding ISRG has become increasingly mixed in recent weeks. While JPMorgan cut its target, Deutsche Bank reduced its price objective to $366.00 and assigned a sell rating. Conversely, HSBC lowered its target but maintained a buy rating, and Sanford Bernstein cut its target while keeping an outperform rating. The aggregate consensus remains a Moderate Buy with an average price target of $523.46.
Despite the recent analyst downgrades, Intuitive Surgical reported strong quarterly fundamentals in late April. The company posted earnings per share of $2.50, beating estimates of $2.08, and generated revenue of $2.77 billion, which exceeded expectations of $2.62 billion. Revenue grew 23% year-over-year, supported by a net margin of 28.45% and a return on equity of 17.09%.
Institutional ownership remains robust at 83.64%, with notable activity from hedge funds in the fourth quarter. Newbridge Financial Services Group Inc. increased its position by 300%, while Turning Point Benefit Group Inc. grew its stake by over 800%. The company maintains a market capitalization of $122.33 billion and trades at a P/E ratio of 39.57.
📉 Analysts cut price targets to $366–$450 amid bearish sentiment.
💰 Q1 revenue hit $2.77B, beating estimates by $150M.
📈 EPS reached $2.50, surpassing the $2.08 consensus estimate.
🚀 Revenue grew 23% YoY driven by robotic system demand.
🎯 Average analyst target is $523.46 with a Moderate Buy rating.
📉 JPMorgan Chase lowered its price target on Intuitive Surgical from $550.00 to $450.00, causing shares to gap down significantly.
📊 Deutsche Bank reduced its price target to $366.00 and issued a sell rating, adding to recent bearish analyst sentiment.
💰 Intuitive Surgical reported Q1 revenue of $2.77 billion, beating analyst estimates of $2.62 billion by $150 million.
📈 Earnings per share reached $2.50, surpassing the consensus estimate of $2.08 by a margin of $0.42.
🚀 Revenue grew 23% year-over-year, driven by strong demand for robotic-assisted surgical systems.
💵 The company achieved a net margin of 28.45% and a return on equity of 17.09% during the quarter.
🏦 Institutional ownership stands at 83.64%, indicating continued confidence from major investors.
📉 Hedge fund activity was mixed, with Newbridge Financial increasing its stake by 300% while others acquired new positions.
🎯 The average analyst price target remains $523.46, suggesting a Moderate Buy consensus despite recent cuts.
📉 Technical indicators show the stock trading below its 50-day moving average of $415.28 and 200-day average of $467.88.
Bullish Signals
Revenue beat estimates at $2.77 billion.
Earnings per share hit $2.50, beating consensus.
Revenue grew 23% year-over-year.
Net margin reached 28.45% with ROE of 17.09%.
Institutional ownership stands at 83.64%.
Risk Factors
JPMorgan cut target to $450.00 causing sharp gap down.
Deutsche Bank lowered target to $366.00 with sell rating.
Stock trades below 50-day ($415.28) and 200-day ($467.88) averages.
Mizuho and Weiss Ratings issued neutral or hold ratings.
Bullish Signals
Intuitive Surgical reported revenue of $2.77 billion, which beat analyst estimates of $2.62 billion.
The company posted earnings per share of $2.50, significantly beating the consensus estimate of $2.08.
Revenue grew 23% year-over-year, demonstrating strong top-line growth in its core business.
The firm achieved a healthy net margin of 28.45% and a return on equity of 17.09%.
Institutional ownership remains high at 83.64%, with several hedge funds increasing their stakes in Q4.
Risk Factors
JPMorgan Chase lowered its price target from $550.00 to $450.00, triggering a sharp gap down in the stock.
Deutsche Bank reduced its price target to $366.00 and assigned a sell rating to the company.
The stock is currently trading below both its 50-day moving average ($415.28) and 200-day moving average ($467.88).
Several other analysts, including Mizuho and Weiss Ratings, have issued neutral or hold ratings on the stock.
Intuitive Surgical (ISRG) reported robust second-quarter 2026 financial results, driven by significant growth in both its core da Vinci and newer Ion robotic surgery platforms. Total revenue reached $2.89 billion, representing a 19% year-over-year increase from the prior year's $2.44 billion. This expansion was fueled by a 15% rise in da Vinci procedure volume and a substantial 36% surge in Ion procedure volume, alongside higher leasing revenue for its surgical systems.
The company demonstrated strong operational performance with GAAP income from operations climbing to $972 million, up from $743 million in the previous year. Non-GAAP income from operations also saw a notable increase to $1.22 billion compared to $0.95 billion. Net income attributable to Intuitive Surgical rose to $818 million, or $2.29 per diluted share, reflecting improved profitability and cash generation capabilities despite higher share-based compensation expenses.
Intuitive concluded the quarter with a healthy balance sheet, holding $8.63 billion in cash, cash equivalents, and investments, an increase of $650 million driven by operational cash flow. CEO Dave Rosa highlighted the strength of the company's portfolio, emphasizing the successful integration of digital solutions alongside its established robotic systems to deliver better patient outcomes and broader access to minimally invasive care globally.
📈 Q2 2026 revenue surged 19% to $2.89 billion.
🔬 Instruments revenue grew 18% to $1.73 billion.
🤖 da Vinci placements rose to 468 units, including 246 da Vinci 5s.
💰 GAAP income expanded to $972 million; cash reached $8.63 billion.
🚀 Ion procedure volume jumped 36% year-over-year.
📈 Second quarter 2026 revenue surged to $2.89 billion, marking a 19% increase from the same period in 2025.
🔬 Instruments and accessories revenue grew by 18% to $1.73 billion, driven by higher procedure volumes across both da Vinci and Ion systems.
🤖 Systems revenue reached $685 million, reflecting increased placements of 468 da Vinci surgical systems compared to 395 in the prior year.
💰 GAAP income from operations expanded to $972 million, while non-GAAP income from operations rose to $1.22 billion.
📉 Net income attributable to Intuitive Surgical hit $818 million, translating to $2.29 per diluted share versus $1.81 in the previous year.
💵 The company ended the quarter with $8.63 billion in cash and investments, up $650 million from the start of the period.
🚀 Ion procedure volume experienced a significant 36% growth rate compared to the second quarter of 2025.
📊 da Vinci system placements included 246 units of the newer da Vinci 5 model, showing continued adoption of advanced technology.
🌍 CEO Dave Rosa emphasized the company's commitment to helping customers deliver better patient outcomes and lower costs globally.
Bullish Signals
Revenue grew 19% year-over-year to $2.89 billion.
Instruments revenue increased 18% to $1.73 billion.
Ion procedure volume surged 36%.
GAAP income from operations rose 31% to $972 million.
Non-GAAP net income per share reached $2.80.
Placed 468 da Vinci systems in the quarter.
Cash and investments grew to $8.63 billion.
Bullish Signals
Revenue grew 19% year-over-year to $2.89 billion, demonstrating strong market demand for minimally invasive care solutions.
Instruments and accessories revenue increased by 18% to $1.73 billion, indicating robust recurring revenue streams from existing installed bases.
Ion procedure volume surged 36%, signaling successful adoption of the company's newer endoluminal system technology.
GAAP income from operations rose 31% to $972 million, reflecting improved operational efficiency and margin expansion.
Non-GAAP net income per diluted share increased to $2.80 from $2.19 in the prior year, showing strong underlying profitability.
The company placed 468 da Vinci systems in the quarter, including 254 under operating lease arrangements, expanding its recurring revenue model.
Cash and investments grew by $650 million to reach $8.63 billion, providing ample liquidity for future growth initiatives or share repurchases.
Bank of New York Mellon Corp reduced its stake in Intuitive Surgical, Inc. (ISRG) by 9.4% during the first quarter, selling 369,852 shares. Following this transaction, BNY Mellon holds approximately 1.00% of the company's stock, valued at $1.637 billion. While major institutions trim positions, several smaller hedge funds and wealth management firms increased their holdings in the fourth quarter, though these new stakes are relatively minor in total value compared to the large institutional owner.
Analyst sentiment regarding ISRG remains mixed but generally positive, with a consensus rating of 'Moderate Buy' and a target price of $565.31. Recent analyst actions include Citigroup reissuing a 'buy' rating, Goldman Sachs setting a $558 price objective, and Piper Sandler reaffirming an 'overweight' rating with a $580 target. Conversely, Jefferies Financial Group cut its price objective to $515 and assigned a 'hold' rating, while Raymond James lowered its target to $577.
Intuitive Surgical reported strong financial performance in the quarter ended April 21st, posting earnings per share of $2.50 against a consensus estimate of $2.08. Revenue reached $2.77 billion, representing a 23% year-over-year increase compared to analyst expectations of $2.62 billion. The company achieved a net margin of 28.15% and a return on equity of 15.98%, with equities research analysts forecasting an EPS of 8.57 for the current fiscal year.
The medical technology company, headquartered in Sunnyvale, California, specializes in robotic-assisted surgical systems like the da Vinci platform. With a market capitalization of $137.76 billion and a P/E ratio of 47.15, ISRG trades above its 200-day simple moving average of $469.98 but below its 50-day average of $418.39. The stock has seen significant volatility over the past year, ranging from a low of $378.50 to a high of $603.88.
📉 BNY Mellon sold 369,852 shares, reducing stake by 9.4%.
💰 Revenue hit $2.77B, beating estimates by $150M.
📈 EPS reached $2.50, surpassing the $2.08 consensus.
🚀 Revenue grew 23% year-over-year on strong demand.
🎯 Consensus analyst target price is set at $565.31.
📉 Bank of New York Mellon Corp sold 369,852 shares of ISRG in Q1, reducing its position by 9.4% while retaining a stake worth $1.637 billion.
📈 Several smaller institutional investors increased their stakes in Q4, including Newbridge Financial Services Group which lifted holdings by 300%.
💰 Intuitive Surgical reported quarterly revenue of $2.77 billion, beating analyst estimates of $2.62 billion by $150 million.
📊 The company posted EPS of $2.50, surpassing the consensus estimate of $2.08 and achieving a net margin of 28.15%.
🚀 Revenue grew 23% year-over-year, demonstrating continued strong demand for robotic surgical systems.
📝 Citigroup reissued a 'buy' rating on ISRG, while Goldman Sachs set a price objective of $558.
⚠️ Jefferies Financial Group cut its price target to $515 and downgraded the stock to a 'hold' rating.
🎯 Piper Sandler reaffirmed an 'overweight' rating with a price target of $580 on ISRG shares.
📉 The consensus analyst target price for Intuitive Surgical is currently set at $565.31.
📈 The stock trades at a P/E ratio of 47.15 with a market capitalization of $137.76 billion.
🏥 ISRG specializes in da Vinci surgical systems that enable minimally invasive procedures for hospitals.
📉 The stock price has fluctuated between a twelve-month low of $378.50 and a high of $603.88.
Bullish Signals
Beat EPS estimates at $2.50 vs $2.08 consensus.
Revenue grew 23% YoY to $2.77 billion.
Net margin stands at 28.15% with ROE of 15.98%.
Citigroup reissued 'buy' rating on ISRG.
Piper Sandler set price target at $565.31.
Risk Factors
Jefferies cut target to $515 with 'hold' rating.
Raymond Financial lowered target from $615 to $577.
BNY Mellon reduced holdings by 9.4%.
High P/E of 47.15 limits upside if growth slows.
Bullish Signals
Intuitive Surgical beat quarterly earnings estimates significantly, reporting $2.50 EPS versus the consensus of $2.08.
Revenue growth remains robust at 23% year-over-year, reaching $2.77 billion for the quarter.
The company maintains healthy profitability with a net margin of 28.15% and a return on equity of 15.98%.
Citigroup reissued a 'buy' rating on ISRG, reinforcing positive analyst sentiment.
Piper Sandler reaffirmed an 'overweight' rating with a price target of $580.
Analyst consensus remains 'Moderate Buy' with a collective target price of $565.31.
Risk Factors
Jefferies Financial Group cut its price objective to $515 and assigned a 'hold' rating, indicating some caution.
Raymond Financial reduced its price target from $615 to $577 despite maintaining an 'outperform' rating.
BNY Mellon's significant reduction in holdings by 9.4% suggests institutional investors are trimming exposure.
The stock trades at a high P/E ratio of 47.15, which may limit upside potential if growth slows.
Institutional ownership of Intuitive Surgical, Inc. (NASDAQ:ISRG) saw mixed activity in the first quarter, with AMF Tjanstepension AB reducing its stake by 19.4% to 171,089 shares valued at $78.87 million. Conversely, several other major funds increased their positions significantly, including Teachers Retirement System of Kentucky boosting holdings by 72.6% and LGT Fund Management Co Ltd increasing its stake by 565.6%. These shifts reflect varying institutional strategies regarding the medical robotics leader.
Analyst sentiment remains cautiously optimistic despite a recent downgrade from Zacks Research, which changed its rating to 'hold.' Other major firms like Barclays and BTIG maintain 'overweight' or 'buy' ratings with price targets ranging from $574 to $651. The consensus average price target sits at $569.20, while the stock trades near its 50-day moving average of $422.09.
Insider trading activity shows executives Gary Loeb and Iman Jeddi sold shares totaling over $3 million in the last 90 days under pre-arranged Rule 10b5-1 plans. These sales represent a decrease in their personal holdings but are disclosed as part of standard trading plans rather than immediate negative signals about company fundamentals.
📉 AMF Tjanstepension AB sold 41,307 shares, reducing position by 19.4%.
📈 Teachers Retirement System of Kentucky added 20,280 shares, up 72.6%.
🚀 LGT Fund Management Co Ltd increased holding by 565.6% in Q1.
📉 Zacks Research downgraded stock from 'strong-buy' to 'hold'.
💰 Barclays maintains 'overweight' rating with $651 price objective.
📉 AMF Tjanstepension AB lowered its ISRG position by 19.4% during Q1, selling 41,307 shares.
📈 Teachers Retirement System of Kentucky increased its stake by 72.6%, acquiring an additional 20,280 shares.
🚀 LGT Fund Management Co Ltd grew its ISRG holding by 565.6% in the first quarter.
📊 Zacks Research downgraded Intuitive Surgical from 'strong-buy' to 'hold' on March 30th.
💰 Barclays maintains an 'overweight' rating with a $651 price objective for ISRG.
👔 EVP Gary Loeb sold 400 shares worth $169,656 under a Rule 10b5-1 trading plan.
📉 SVP Iman Jeddi reduced his personal stake by 46.53% via a sale of 5,625 shares.
🏢 Institutional investors collectively own 83.64% of Intuitive Surgical's outstanding stock.
📈 The company has a market capitalization of $144.07 billion and a PEG ratio of 3.31.
🎯 MarketBeat consensus price target for ISRG is set at $569.20.
Bullish Signals
Teachers Retirement and LGT increased stakes Q1.
Barclays rates overweight with $651 price target.
Risk Factors
Zacks downgraded Intuitive Surgical from strong-buy to hold.
Truist cut price target from $650 to $580.
Bullish Signals
Multiple institutional investors, including Teachers Retirement System and LGT Fund Management, significantly increased their stakes in the first quarter, indicating confidence in the company's long-term prospects.
Major analysts like Barclays maintain an 'overweight' rating with a high price target of $651, suggesting strong future growth potential relative to current valuation.
Risk Factors
Zacks Research recently downgraded Intuitive Surgical from a 'strong-buy' to a 'hold' rating, signaling some analysts see limited near-term upside.
Truist Financial reduced its price objective from $650 to $580, reflecting a more conservative valuation outlook for the stock.
Intuitive Surgical (ISRG) is preparing to release its Q2 2026 earnings results after market close on Thursday, July 16th. Analysts project the company will report earnings per share of $2.48 and revenue of $2.8249 billion for the quarter. The upcoming earnings call is scheduled for 4:30 PM ET, with investors encouraged to review the latest summary page for details on the conference.
The medical technology firm previously reported strong financials in April, posting $2.50 EPS which significantly beat analyst consensus estimates of $2.08 by $0.42. Revenue reached $2.77 billion, surpassing expectations of $2.62 billion, while net margins stood at 28.15% and year-over-year revenue growth was a robust 23.0%. Analysts maintain forward guidance with average EPS expectations of $9 for the current fiscal year and $10 for the next.
Recent insider activity shows mixed signals as Director Amy Ladd sold 119 shares in April under a pre-arranged trading plan, while EVP Gary Loeb reduced his position by 6.54% in June. Despite these sales, institutional investors have been accumulating stakes, with Brighton Jones LLC increasing its holdings by 24.9% and Meeder Asset Management Inc. boosting its position by over 150% in the fourth quarter.
Intuitive Surgical continues to dominate the robotic-assisted surgery market with its da Vinci systems, which enable minimally invasive procedures for hospitals and surgical centers. The company generates revenue through the sale of surgical platforms, reusable and disposable instruments, proprietary software, and essential training and servicing support. With a market cap of $147 billion and a PE ratio of 50.32, the stock trades near its 50-day moving average.
📅 Q2 2026 earnings release scheduled for Thursday, July 16th.
💰 Last quarter beat estimates with $2.50 EPS and $2.77B revenue.
🏆 Achieved 28.15% net margin and 15.98% return on equity.
🔬 Core business relies on da Vinci surgical systems for hospitals.
📅 Intuitive Surgical is set to release Q2 2026 earnings on Thursday, July 16th, with analysts expecting $2.48 EPS and $2.8249 billion in revenue.
💰 The company previously beat estimates in April with $2.50 EPS versus a consensus of $2.08 and revenue of $2.77 billion against expectations of $2.62 billion.
📈 Revenue grew 23.0% year-over-year in the last reported quarter, demonstrating strong top-line momentum for the medical device leader.
🏆 Intuitive Surgical achieved a net margin of 28.15% and a return on equity of 15.98% during its last earnings period.
📉 Director Amy Ladd sold 119 shares in April, while EVP Gary Loeb reduced his stake by 6.54% in June under Rule 10b5-1 plans.
🏛️ Institutional ownership remains high at 83.64%, with Brighton Jones LLC increasing its stake by 24.9% and Meeder Asset Management Inc. adding 153.2% to its position.
📊 The stock currently trades at a PE ratio of 50.32 with a market capitalization of $147.01 billion.
🔬 The company's core business revolves around the da Vinci surgical systems, which provide minimally invasive capabilities to hospitals and surgical centers.
💻 Revenue streams include sales of surgical platforms, instruments, accessories, proprietary software, as well as training and clinical support services.
Bullish Signals
Beat estimates with $2.50 EPS vs $2.08 consensus.
Revenue grew 23.0% year-over-year last quarter.
Net margins remained healthy at 28.15%.
Analysts project $9 and $10 EPS for next two years.
Risk Factors
Director Amy Ladd sold 119 shares, reducing position by nearly 50%.
EVP Gary Loeb sold 400 shares, decreasing ownership by 6.54%.
Insiders collectively sold over $3 million in 7,169 shares last three months.
Bullish Signals
The company recently beat analyst estimates significantly with $2.50 EPS compared to a consensus of $2.08, indicating strong operational execution.
Revenue grew 23.0% year-over-year in the last reported quarter, showcasing robust demand for its robotic surgical systems.
Net margins remained healthy at 28.15%, reflecting the company's pricing power and efficient cost structure in the medical device sector.
Major institutional investors like Brighton Jones LLC and Meeder Asset Management Inc. have significantly increased their stakes, signaling confidence in the long-term outlook.
Analysts project $9 EPS for the current fiscal year and $10 for the next, suggesting sustained growth expectations from Wall Street.
Risk Factors
Director Amy Ladd sold 119 shares in April, reducing her position by nearly 50%, which could indicate a lack of immediate confidence or portfolio rebalancing.
EVP Gary Loeb sold 400 shares in June, decreasing his ownership by 6.54%, adding to the narrative of insider selling activity.
Insiders have collectively sold over $3 million worth of stock in the last three months, totaling 7,169 shares, which may warrant attention from value investors.
Intuitive Surgical has introduced the EndoWrist Stapler 45, a single-patient-use robotic stapling instrument designed for its da Vinci Xi and X systems. This new accessory enables wristed articulation and integrated software confirmation for clamp and firing conditions, specifically targeting complex colorectal and thoracic procedures such as low anterior resections and sigmoid colectomies.
The device is intended to extend the dexterity of Intuitive's robotic platform by allowing surgeons to perform stapling and transection tasks entirely within the robotic system, eliminating the need to switch to handheld laparoscopic devices. Clinical observations suggest this integration improves workflow and control in deep pelvic cases, though total operating room time remains higher than conventional laparoscopy.
Financially, the EndoWrist Stapler 45 contributes to Intuitive Surgical's recurring revenue model, which analysts note now accounts for over 70% of total sales. The instrument is reimbursed as part of the overall procedure cost in the US, with per-case pricing negotiated through multi-year purchasing agreements that typically involve multiple reloads per surgery.
Intuitive segments these instruments under 'Instruments and Accessories' in SEC filings, a category that grew double digits year-over-year in 2025. With over 9,000 da Vinci systems installed worldwide, the recurring revenue from accessories like this stapler remains a key metric for investors tracking the company's financial performance and growth trajectory.
🔧 Intuitive Surgical launches da Vinci-compatible EndoWrist Stapler 45.
📈 Single-use accessories now drive over 70% of total sales.
📊 Instruments segment grew double digits in 2025 on high volume.
🏥 US reimbursement covers stapler cost within overall procedure fees.
🔬 Studies show reduced open surgery conversion rates for pelvic cases.
🔧 Intuitive Surgical launches the EndoWrist Stapler 45, a single-patient-use robotic stapling instrument compatible with da Vinci Xi and X systems.
📈 The new accessory supports complex colorectal and thoracic procedures by enabling wristed articulation and integrated software checks for clamp and firing conditions.
💰 Recurring revenue from single-use accessories like this stapler now constitutes more than 70% of Intuitive Surgical's total sales.
📊 The 'Instruments and Accessories' segment grew double digits year-over-year in 2025, driven by high procedure volumes on the installed da Vinci base.
🏥 In the US market, the stapler is reimbursed as part of the overall procedure cost rather than billed separately to patients.
🔬 Clinical studies indicate robotic stapling can reduce conversion rates to open surgery in difficult pelvic cases compared to conventional methods.
⚙️ The device uses 45 mm reload cartridges with color-coding and software checks to reduce risks of misfires or improper tissue compression.
👨⚕️ Surgeons utilize the instrument for tasks like dividing bowel and mesentery, maintaining full robotic control without switching to handheld devices.
💵 Per-case instrument costs are negotiated in multi-year agreements, typically ranging from mid-three-digit to low-four-digit dollars when combining staplers and reloads.
Bullish Signals
EndoWrist Stapler 45 extends da Vinci dexterity for stapling.
Recurring accessory revenue exceeds 70% of total sales.
Instruments segment achieved double-digit year-over-year growth in 2025.
Robotic stapling reduces conversion to open surgery in pelvic cases.
The EndoWrist Stapler 45 extends the da Vinci system's dexterity to stapling tasks that previously required laparoscopic devices, enhancing clinical workflow.
Recurring revenue from single-use accessories now makes up over 70% of Intuitive Surgical's total sales, providing a stable financial foundation.
The 'Instruments and Accessories' segment achieved double-digit year-over-year growth in 2025, highlighting the strength of the consumables business model.
Clinical data suggests robotic stapling reduces conversion rates to open surgery in difficult pelvic cases, potentially improving patient outcomes.
Risk Factors
Total operating room time and cost for robotic procedures remain higher than conventional laparoscopy according to comparative datasets cited by hospital cost committees.
The instrument is reimbursed as part of the overall procedure cost rather than billed separately, which may limit standalone pricing power.
Piper Sandler has restated its rating on Intuitive Surgical (ISRG) to Overweight with a $580 price target, citing solid fundamentals and dismissing prevailing market concerns as exaggerated. A recent field check with a prominent U.S. healthcare institution confirmed the company's positive standing, noting significant expertise in the da Vinci system, particularly the DV5 model.
The analyst firm identified several long-term growth catalysts for Intuitive Surgical, including expansion into ambulatory surgery centers, new cardiovascular treatments using the DV5 system, and the My Intuitive+ platform. Additionally, upgrades to the da Vinci 5 robotic surgical system featuring improved telepresence and longer tool use are expected to be ready in June, pending regulatory clearance.
Despite acknowledging investment risks, Piper Sandler maintains conviction in ISRG's business model. However, the article concludes with a promotional pitch suggesting that certain AI stocks offer higher returns over shorter timeframes than Intuitive Surgical, directing readers to other reports for potential high-upside opportunities.
📈 Piper Sandler rates Intuitive Surgical Overweight with $580 target.
🏥 Major U.S. hospital confirms strong da Vinci system expertise.
🚀 Growth driven by ASC expansion, new treatments, and My Intuitive+.
⚙️ da Vinci 5 upgrades expected in June pending regulatory clearance.
💬 Piper Sandler says fundamental concerns are exaggerated.
📈 Piper Sandler restated its rating on Intuitive Surgical (ISRG) to Overweight with a $580 price target.
🏥 A field check with a major U.S. healthcare institution confirmed strong expertise in the da Vinci system and DV5 model.
🚀 Key growth catalysts include ambulatory surgery center expansion, new cardiovascular treatments, and the My Intuitive+ platform.
⚙️ Upgrades to the da Vinci 5 system, including improved telepresence and longer tool use, are expected in June subject to regulatory clearance.
💬 Piper Sandler asserts that prevailing concerns about the company's fundamentals are blown out of proportion.
📉 The article includes a promotional pitch suggesting other AI stocks may offer higher returns than ISRG.
Bullish Signals
Piper Sandler upgraded rating to Overweight with $580 target.
Healthcare field check confirmed significant expertise in da Vinci system.
Expansion into ambulatory centers and new cardiovascular treatments via DV5.
da Vinci 5 upgrades expected to launch in June.
Risk Factors
General investment risks acknowledged but unspecified as material.
Da Vinci 5 upgrades face regulatory clearance delays.
Bullish Signals
Piper Sandler has upgraded its rating to Overweight and set a $580 price target, indicating strong institutional confidence in the company's long-term viability.
A field check with a prominent healthcare institution confirmed significant expertise in Intuitive Surgical's da Vinci system, validating market adoption.
The company is pursuing multiple growth catalysts including expansion into ambulatory surgery centers and new cardiovascular treatments via the DV5 model.
Upgrades to the da Vinci 5 robotic surgical system are expected to launch in June, potentially enhancing product capabilities and competitive positioning.
Risk Factors
The article notes that Piper Sandler acknowledges general investment risks associated with ISRG, though it does not specify them as material threats.
Upgrades to the da Vinci 5 system are explicitly stated to be subject to regulatory clearance, introducing a potential delay or approval risk.
Intuitive Surgical (ISRG) reported standout Q1 2023 results, beating analyst estimates with revenue of $1.70 billion, a 14% year-over-year increase, and adjusted earnings of $1.23 per share versus the expected $1.20. The surge was driven by a 26% jump in procedure volumes as hospitals cleared post-pandemic backlogs. Consequently, management raised its full-year procedure growth forecast to 18–21%, up from the previous 12–16% range, signaling robust demand ahead.
The company maintains an exceptionally strong balance sheet with virtually no debt and a cash reserve of $6.58 billion as of Q1 2023. Intuitive has never paid a cash dividend, instead returning capital through significant share repurchases, including $350 million in the first quarter alone. This conservative capital structure provides ample flexibility for R&D, acquisitions, and shareholder returns without financial strain.
Despite its strengths, ISRG faces risks including competition from major medical device firms like Medtronic and Johnson & Johnson developing their own robotic platforms. The stock trades at a premium valuation of approximately 70x trailing earnings, reflecting high growth expectations but also exposing it to potential volatility if growth slows or legal challenges regarding antitrust practices materialize.
Analysts note that flatlining growth in new system placements and a shift toward leasing arrangements could signal market saturation or increased cost sensitivity among customers. Additionally, the sustainability of procedure growth after backlog normalization and the timing of the next-generation robotic system launch remain key uncertainties for investors monitoring the company's future trajectory.
📈 Q1 2023 revenue hit $1.70B, up 14% YoY.
💰 Adjusted EPS reached $1.23, beating the $1.20 forecast.
Intuitive Surgical (ISRG) saw significant institutional activity in the first quarter, led by Fjarde AP Fonden boosting its stake by 57.7% to a value of $59.68 million. Several other smaller investors also increased or initiated positions, while institutional ownership remains high at 83.64%. Conversely, insider selling was notable, with EVP Gary Loeb and Director Amy Ladd reducing their holdings under pre-arranged trading plans, totaling over $3 million in sales during the quarter.
Analyst sentiment for ISRG is mixed but generally positive, with a consensus price target of $573.42 based on 19 Buy ratings versus 7 Hold and 1 Sell. Recent reports include TD Cowen lowering its target to $585 while maintaining a Buy rating, Mizuho setting a neutral target at $525, and Zacks Research downgrading the stock from Strong-Buy to Hold. The average analyst price target reflects a moderate buy consensus despite some recent downgrades.
Financially, Intuitive Surgical reported strong Q1 results with revenue of $2.77 billion, beating estimates by 5.7% and growing 23% year-over-year. The company posted $2.50 EPS, significantly above the $2.08 consensus, resulting in a net margin of 28.15%. With a market cap of $150.88 billion and a P/E ratio of 51.64, the stock trades above its 200-day moving average but below its 52-week high, reflecting recent volatility.
📈 Fjarde AP Fonden increased ISRG stake by 57.7% to $59.68 million.
💰 Q1 revenue hit $2.77 billion, beating estimates with $2.50 EPS.
📉 EVP Gary Loeb sold $169,656 of shares under Rule 10b5-1 plans.
Intuitive Surgical (NASDAQ:ISRG) saw a mixed institutional landscape in the first quarter, highlighted by ABN AMRO Bank N.V. reducing its stake by 37.1% to 40,572 shares, worth approximately $18.9 million. Conversely, several smaller hedge funds including Riversedge Advisors LLC and Fiduciary Financial Group LLC increased their positions slightly during the fourth quarter, while WoodTrust Financial Corp also added to its holdings.
Analyst sentiment remains cautiously positive despite recent downgrades from major firms like Zacks Research and UBS Group, which lowered price targets. The consensus rating is a 'Moderate Buy' with a target price of $573.42, though the stock recently traded below its 50-day moving average. Insider selling activity was notable in April and June, with directors and senior executives executing pre-arranged Rule 10b5-1 trades to reduce their personal holdings.
Financially, Intuitive Surgical delivered strong performance in the quarter ending April 21st, reporting revenue of $2.77 billion, a 23% year-over-year increase that beat analyst expectations. The company posted earnings per share of $2.50 against a consensus of $2.08, resulting in a net margin of 28.15%. With a market capitalization of $143.33 billion and a P/E ratio of 49.05, the medical robotics leader continues to demonstrate robust growth driven by its da Vinci surgical systems.
📉 ABN AMRO sold shares, reducing stake by 37.1% to $18.89 million value.
📈 Q1 revenue hit $2.77 billion, beating estimates with EPS of $2.50.
📉 Analysts lowered targets to $558 and $550 despite 'Moderate Buy' rating.
🏦 Insider selling occurred in April and June via Rule 10b5-1 plans.
📉 Stock trades at $404.70, below 50-day and 200-day moving averages.
📉 ABN AMRO Bank N.V. decreased its ISRG position by 37.1% in Q1, selling 23,961 shares while retaining a stake valued at $18.89 million.
📈 Several smaller hedge funds including Riversedge Advisors LLC and WoodTrust Financial Corp increased their stakes in the fourth quarter.
📊 Intuitive Surgical reported Q1 revenue of $2.77 billion, representing a 23% year-over-year increase compared to analyst expectations of $2.62 billion.
💰 The company posted earnings per share of $2.50, significantly topping the consensus estimate of $2.08 with a net margin of 28.15%.
📉 Analyst sentiment is mixed with recent downgrades from Zacks Research and UBS Group lowering price targets to $558 and $550 respectively.
🏦 The stock maintains a consensus 'Moderate Buy' rating with an average target price of $573.42 based on 19 buy, 7 hold, and 1 sell ratings.
📉 Insider selling activity was significant in April and June, with directors and SVPs reducing holdings via pre-arranged Rule 10b5-1 trading plans.
📈 The company has a market capitalization of $143.33 billion and trades at a P/E ratio of 49.05.
🔬 Intuitive Surgical is best known for its da Vinci surgical systems which enable minimally invasive procedures in hospitals and surgical centers.
📉 The stock opened at $404.70, trading below its 50-day moving average of $432.67 and 200-day moving average of $484.61.
Bullish Signals
Q1 revenue hit $2.77 billion, up 23% year-over-year.
Earnings per share reached $2.50, beating estimates by $0.42.
Net margin of 28.15% and ROE of 15.98% reported.
Analysts rate stock 'Moderate Buy' with $573.42 target.
Risk Factors
Zacks Research downgraded Intuitive Surgical to 'hold' on March 30th.
UBS cut price target from $570.00 to $550.00 with neutral rating.
Bank of America lowered price target from $520.00 to $515.00.
ABN AMRO Bank reduced position by 37.1% in first quarter.
Insiders sold 7,169 shares worth $3.06 million last quarter.
Bullish Signals
Intuitive Surgical reported Q1 revenue of $2.77 billion, a 23% year-over-year increase that exceeded analyst expectations of $2.62 billion.
The company posted earnings per share of $2.50, beating the consensus estimate of $2.08 by $0.42.
Intuitive Surgical achieved a strong net margin of 28.15% and a return on equity of 15.98% for the quarter.
The stock maintains a consensus 'Moderate Buy' rating from nineteen equities research analysts with a target price of $573.42.
Risk Factors
Zacks Research lowered its rating on Intuitive Surgical from 'strong-buy' to 'hold' in a report dated March 30th.
UBS Group decreased its price target from $570.00 to $550.00 and set a 'neutral' rating in a report dated March 17th.
Bank of America dropped its price target from $520.00 to $515.00 in a research note dated June 12th.
Major institutional investor ABN AMRO Bank N.V. significantly reduced its position by 37.1% during the first quarter.
Insiders sold a total of 7,169 shares valued at $3.06 million over the last quarter, indicating some internal profit-taking.
Aaron Wealth Advisors LLC reduced its stake in Intuitive Surgical, Inc. (ISRG) by 21.9% in the first quarter, selling 1,377 shares and holding a remaining position of 4,903 shares valued at $2.26 million. This move was part of broader institutional activity where other firms like Brighton Jones LLC increased their holdings by 24.9%, while Sivia Capital Partners, Schnieders Capital Management, Osterweis Capital Management, and Main Street Financial Solutions also adjusted or initiated positions in the second quarter.
Intuitive Surgical reported strong financial performance for the quarter ended April 21st, with revenue of $2.77 billion representing a 23.0% year-over-year increase. The company posted earnings per share of $2.50, significantly beating the consensus estimate of $2.08, and achieved a net margin of 28.15%. Analysts maintain an average rating of 'Moderate Buy' with a consensus price target of $573.42, though recent analyst actions include Citigroup upgrading to 'Buy' while Leerink Partners, TD Cowen, and Goldman Sachs lowered their price targets.
The medical technology company, known for its da Vinci surgical systems, continues to operate with a market capitalization of $141.55 billion. Despite the stock trading near its 50-day moving average of $433.94, the firm's robust earnings beat and high institutional ownership of 83.64% suggest continued confidence in its robotic-assisted surgery platform. The mixed analyst price targets reflect a cautious but generally positive outlook on the company's growth trajectory.
📉 Aaron Wealth Advisors cut ISRG stake by 21.9% in Q1.
📈 Brighton Jones LLC increased position by 24.9% in Q4.
📊 Intuitive Surgical reported Q1 revenue of $2.77 billion, up 23%.
💰 EPS reached $2.50, beating estimates by $0.42.
🏦 Citigroup upgraded rating to 'Buy' with $590 price target.
📉 Aaron Wealth Advisors LLC cut its ISRG stake by 21.9% in Q1, selling 1,377 shares while retaining 4,903 shares valued at $2.26 million.
📈 Brighton Jones LLC increased its position by 24.9% in Q4 to own 3,672 shares worth $1.92 million.
📊 Intuitive Surgical reported Q1 revenue of $2.77 billion, a 23.0% increase compared to the same quarter last year.
💰 The company posted earnings per share of $2.50, topping analyst estimates of $2.08 by $0.42.
📉 Net margin for the quarter reached 28.15%, demonstrating strong profitability on the reported revenue.
🏦 Citigroup upgraded its rating to 'Buy' with a $590 price target, while other firms like Goldman Sachs and TD Cowen lowered targets.
📈 Institutional investors own 83.64% of the company's outstanding stock, indicating high institutional confidence.
🏢 The firm operates with a market capitalization of $141.55 billion and trades at a P/E ratio of 48.45.
📉 The stock price is currently trading near its 50-day moving average of $433.94 after hitting a twelve-month high of $603.88.
🔬 Intuitive Surgical focuses on robotic-assisted surgical systems like the da Vinci platform to improve operating room precision.
Bullish Signals
Revenue hit $2.77 billion, up 23.0% year-over-year.
Beat earnings with $2.50 EPS vs $2.08 estimate.
Net margin expanded to 28.15%.
Citigroup upgraded to buy with $590 price target.
Institutional ownership stands at 83.64%.
Risk Factors
Major analysts including Goldman Sachs recently lowered price targets.
Stock trades below 200-day moving average of $485.17.
PEG ratio of 3.27 suggests stock priced for high growth.
Bullish Signals
Intuitive Surgical reported revenue of $2.77 billion, which represents a significant 23.0% year-over-year growth.
The company beat earnings expectations with $2.50 EPS compared to the consensus estimate of $2.08.
Net margin expanded to 28.15%, highlighting strong operational efficiency and pricing power.
Citigroup upgraded its rating from 'neutral' to 'buy' with a price target of $590.00.
Institutional ownership remains high at 83.64%, suggesting sustained confidence from major investors.
Main Street Financial Solutions LLC significantly grew its stake by 92.4% in the second quarter.
Risk Factors
Several major analysts, including Leerink Partners, TD Cowen, and Goldman Sachs, recently lowered their price targets for ISRG.
The stock is currently trading below its 200-day moving average of $485.17, indicating some short-term weakness.
The PEG ratio stands at 3.27, which may suggest the stock is priced for high growth relative to its earnings expansion.
Intuitive Surgical, Inc. (ISRG) shares closed at $404.27, rising 1.14% despite a broader market decline where the S&P 500 and Nasdaq fell. However, the stock has underperformed over the past month, dropping 5.65% compared to gains in the Medical sector and losses in the wider S&P 500.
Analysts are anticipating strong upcoming earnings with a consensus EPS of $2.48, representing a 13.24% year-over-year increase, and revenue of $2.81 billion, up 15%. Full-year projections suggest earnings of $10.41 per share and revenue of $11.72 billion, both reflecting approximately 16.5% growth from the prior year.
Valuation metrics indicate a premium for ISRG relative to its peers, with a Forward P/E ratio of 38.4 compared to an industry average of 24.67 and a PEG ratio of 2.68 versus 2.23. The company currently holds a Zacks Rank #2 (Buy) rating, while the broader Medical Instruments industry ranks in the bottom 38% of all tracked industries.
📈 ISRG shares rose 1.14% to $404.27, outperforming major indices.
📉 Stock dropped 5.65% this month, lagging the Medical sector.
💰 Analysts forecast quarterly EPS of $2.48 and revenue of $2.81B.
📊 Forward P/E is 38.4x, well above the industry average of 24.67x.
🏆 Holds Zacks Rank #2 (Buy) with stable analyst estimates.
📈 ISRG shares closed up 1.14% at $404.27, outperforming the S&P 500 and Nasdaq during a market dip.
📉 The stock has declined 5.65% over the past month, trailing the Medical sector's positive performance.
💰 Analysts forecast upcoming quarterly EPS of $2.48 (13.24% growth) and revenue of $2.81 billion (15% growth).
📅 Full-year consensus estimates project earnings of $10.41 per share and revenue of $11.72 billion.
📊 The company trades at a Forward P/E of 38.4, significantly higher than the industry average of 24.67.
📉 ISRG has a PEG ratio of 2.68 compared to an industry average of 2.23.
🏆 Intuitive Surgical holds a Zacks Rank #2 (Buy) based on analyst estimate stability.
🏭 The Medical Instruments industry ranks in the bottom 38% of all 250+ industries tracked by Zacks.
Bullish Signals
Shares rose 1.14% to $404.27, outperforming major indices.
EPS projected at $2.48, up 13.24% YoY.
Revenue expected at $2.81 billion, up 15% YoY.
Full-year earnings estimated at $10.41 per share.
Zacks Rank #2 (Buy) rating maintained.
Risk Factors
Stock declined 5.65% while sector and S&P 500 moved differently.
Forward P/E of 38.4 is much higher than industry average of 24.67.
PEG ratio of 2.68 exceeds industry average of 2.23, implying high price.
Bullish Signals
ISRG shares rose 1.14% to close at $404.27, demonstrating resilience and outperformance against major indices like the S&P 500 and Nasdaq during a market downturn.
Upcoming earnings are expected to show robust growth with EPS projected at $2.48 (13.24% YoY) and revenue at $2.81 billion (15% YoY).
Full-year analyst consensus indicates continued expansion with estimated earnings of $10.41 per share and revenue of $11.72 billion, both up approximately 16.5% from last year.
The company maintains a Zacks Rank #2 (Buy) rating, suggesting analysts see stable or improving near-term business trends.
Risk Factors
ISRG has underperformed over the past month with a 5.65% decline, falling short of the Medical sector's gain and the S&P 500's loss.
The stock trades at a Forward P/E ratio of 38.4, which is substantially higher than the industry average of 24.67, indicating a premium valuation.
ISRG's PEG ratio of 2.68 exceeds the industry average of 2.23, suggesting the current price may be high relative to its expected earnings growth rate.
Fisher Funds Management LTD significantly increased its position in Intuitive Surgical (ISRG) by 28.3% in the first quarter, acquiring an additional 31,392 shares to hold a total of 142,156 shares valued at approximately $65.5 million. This move makes ISRG the fund's 10th largest holding, representing 1.9% of its portfolio. Several other institutional investors also adjusted their stakes, with Newbridge Financial Services Group Inc. growing its position by 300% in the fourth quarter, while multiple smaller funds initiated new positions ranging from $25,000 to $31,000.
Analyst sentiment remains mixed but generally positive regarding Intuitive Surgical's long-term prospects, though recent price targets have been lowered by several major firms. Citigroup upgraded its rating to 'buy' with a $590 target, while Raymond James, HSBC, BTIG Research, and TD Cowen all reduced their price objectives between $574 and $585 in late April. Despite these adjustments, the consensus among 19 buy-side analysts remains a 'Moderate Buy' with an average price target of $573.42.
Financially, Intuitive Surgical delivered strong performance in its last quarterly report released on April 21st, beating earnings and revenue estimates. The company reported $2.50 EPS compared to the consensus of $2.08 and generated $2.77 billion in revenue, which exceeded expectations of $2.62 billion. Revenue grew by 23% year-over-year, resulting in a net margin of 28.15% and a return on equity of 15.98%. Analysts forecast full-year EPS of $8.57 for the current fiscal year.
Recent insider activity shows executives selling shares under pre-arranged Rule 10b5-1 trading plans, which is standard practice but worth noting alongside institutional accumulation. SVP Iman Jeddi sold over $2.3 million in shares on June 1st, and EVP Gary Loeb sold approximately $170,000 on June 10th, reducing their individual holdings by roughly 46% and 6.5% respectively. The stock currently trades around $406.78, trading below its 50-day moving average of $438.43 but above its 1-year low of $396.68.
📈 Fisher Funds raised ISRG holdings by 28.3% to $65.5 million.
📊 Q1 EPS beat estimates at $2.50 with revenue of $2.77 billion.
🚀 Revenue grew 23% year-over-year with a net margin of 28.15%.
📉 Citigroup upgraded to 'buy' while other analysts lowered price targets.
🏢 Institutional ownership remains high at 83.64% despite recent insider sales.
📈 Fisher Funds Management LTD raised its ISRG holdings by 28.3% in Q1, adding 31,392 shares to a total position of 142,156 shares valued at $65.5 million.
🏦 Newbridge Financial Services Group Inc. increased its stake by 300% in the fourth quarter, while several other funds initiated new positions totaling over $114,000.
📊 Intuitive Surgical reported Q1 EPS of $2.50, beating analyst estimates of $2.08, and revenue of $2.77 billion, surpassing the consensus of $2.62 billion.
🚀 Revenue grew 23% year-over-year to $2.77 billion, with a net margin of 28.15% and a return on equity of 15.98%.
📉 Citigroup upgraded ISRG to a 'buy' rating with a $590 price target, while other major analysts like Raymond James and HSBC lowered their price targets to the mid-$570s.
👥 Corporate insiders sold approximately $3.06 million in shares recently under pre-arranged Rule 10b5-1 trading plans, reducing their personal holdings.
📉 The stock currently trades at $406.78, which is below its 50-day moving average of $438.43 and 200-day moving average of $489.92.
🏢 Institutional ownership stands at 83.64%, indicating strong interest from large asset managers despite recent insider selling.
🔭 Analysts forecast full-year EPS of $8.57 for the current fiscal year, suggesting continued growth expectations.
🛠️ The company's core business focuses on robotic-assisted surgical systems like the da Vinci platform, which enables minimally invasive procedures.
Bullish Signals
Fisher Funds increased position by 28.3% adding $31M.
Beat EPS estimates with $2.50 vs $2.08 consensus.
Revenue grew 23% YoY to $2.77 billion.
Net margin of 28.15% and ROE of 15.98%.
Citi upgraded to buy with $590 price target.
Risk Factors
Analysts lowered price targets to mid-$570s.
Insiders sold $3.06 million in shares.
Stock trades below $438.43 and $489.92 averages.
Bullish Signals
Fisher Funds Management LTD significantly increased its position by 28.3% in Q1, adding over $31 million in value to its holdings.
Intuitive Surgical beat both EPS and revenue estimates in the last quarter, reporting $2.50 EPS versus a consensus of $2.08.
Revenue grew robustly by 23% year-over-year to reach $2.77 billion, demonstrating strong demand for its robotic surgical systems.
The company achieved a healthy net margin of 28.15% and a return on equity of 15.98%, indicating efficient operations.
Citigroup upgraded the stock to a 'buy' rating with a $590 price target, signaling confidence in future performance.
Analysts forecast full-year EPS of $8.57, reflecting expectations for continued profitability and growth.
Risk Factors
Several major analysts, including Raymond James, HSBC, BTIG Research, and TD Cowen, recently lowered their price targets to the mid-$570s.
Corporate insiders sold approximately $3.06 million in shares recently under pre-arranged Rule 10b5-1 trading plans.
The stock is currently trading below its 50-day moving average of $438.43 and 200-day moving average of $489.92.
Intuitive Surgical (ISRG) is highlighted as potentially undervalued following Q1 2026 data showing strong demand for its da Vinci 5 robotic surgery systems. The company placed 431 units in the quarter, representing a 17% year-over-year increase, driven by an upgrade cycle and higher leasing activity among hospitals.
Despite this operational strength, ISRG's share price has softened significantly, dropping 27.62% year-to-date. However, analysts using Simply Wall St methodology calculate a fair value of $532.46 compared to the recent closing price of $406.78, suggesting the stock is approximately 23.6% undervalued based on projected revenue growth and margin expansion.
The valuation model assumes annual revenue growth of 12%, profit margins expanding to 30%, and a future P/E ratio of 50x. While the analysis points to an opportunity, it acknowledges risks such as slowing procedure volumes or competitive pressure from new systems that could challenge these optimistic assumptions.
📈 Q1 2026: 431 da Vinci systems placed, up 17% YoY.
💰 Stock undervalued at $532.46 fair value vs $406.78 close.
📉 Price down 27.62% YTD despite strong operational metrics.
🔮 Projected 12% annual revenue growth and 30% margins in 5 years.
⚖️ P/E ratio of 48.4x exceeds industry average of 24.4x.
📈 Q1 2026 results show 431 da Vinci systems placed, a 17% year-over-year increase driven by da Vinci 5 upgrades.
💰 Analysts calculate a fair value of $532.46, implying the stock is 23.6% undervalued relative to the recent close of $406.78.
📉 Share price momentum has softened with a 27.62% decline year-to-date despite positive operational metrics.
🔮 Valuation model projects 12% annual revenue growth and expanding profit margins reaching 30% over the next five years.
⚖️ Current P/E ratio of 48.4x is significantly higher than the industry average of 24.4x and fair estimate of 31.3x.
🛡️ The company maintains a strong balance sheet with recurring revenue streams from spare parts and software licenses.
⚠️ Key risks include potential slowdowns in procedure volumes or pricing pressure from competing robotic systems.
Intuitive Surgical (ISRG) reported a record first quarter with revenue climbing 23% to $2.77 billion and earnings per share of $2.50, significantly beating the analyst consensus of $2.08. Despite these strong fundamentals, shares dropped approximately 25% since the start of the year, trading around EUR 358-360, which is more than 15% below their 200-day moving average and well under the January peak of EUR 516.50.
Institutional investor sentiment remains sharply divided following the earnings release. While Sands Capital Management increased its stake by 2.7% to 1.38 million shares, Focus Partners Wealth boosted holdings by nearly 42%, and Vanguard added 11.5%, other major players exited aggressively. Towarzystwo Funduszy Inwestycyjnych PZU SA slashed its position by 83%, Nicholas Investment Partners sold over 87% of their stake, and Deutsche Bank stands alone among analysts as a seller with a price target of $366.
The stock faces headwinds from an FDA warning requiring recalls of specific surgical stapler models, growing competition from Chinese robotic manufacturers, and concerns regarding OpenAI's entry into the robotics sector. Insider sentiment has also turned cautious, with over 7,000 shares sold by insiders in the past 90 days. However, a potential catalyst exists in Japan, where the government is set to expand reimbursement for seven new robotic-assisted procedures in June 2026, expected to boost procedure volumes.
Technical indicators offer little immediate comfort with the stock maintaining 36% volatility and a neutral Relative Strength Index of 44. Analysts remain broadly positive, with 22 out of 31 brokers rating the stock a buy and a mean price target of approximately $571, though Goldman Sachs recently trimmed its target to $558. The company is due to report second-quarter results in July, with analysts forecasting revenue of $2.82 billion; any miss could accelerate the current decline.
📉 Shares fell 25% despite record Q1 revenue of $2.77B and EPS beat.
⚠️ FDA warning triggers recall of specific surgical stapler models.
🏦 Institutional investors diverge sharply with PZU SA cutting stake by 83%.
🤖 Competition intensifies as Chinese makers advance and OpenAI enters robotics.
🇯🇵 Japan's June 2026 reimbursement expansion boosts robotic procedure volumes.
📉 Shares dropped 25% since the start of the year despite a record Q1 where revenue rose 23% to $2.77 billion and EPS beat consensus at $2.50 vs $2.08.
🏦 Institutional investors are diverging sharply; Focus Partners Wealth increased holdings by 42% while PZU SA slashed its stake by 83% and Nicholas Investment Partners sold over 87%.
⚠️ The FDA issued a warning prompting Intuitive Surgical to recall specific models of surgical staplers, creating immediate regulatory risk.
🤖 Competition is intensifying as Chinese manufacturers gain ground in the surgical robot market and OpenAI enters the robotics space.
🇯🇵 A key catalyst is Japan's June 2026 expansion of reimbursement for seven new robotic-assisted procedures, expected to boost volumes in a previously laggard market.
📊 Analyst sentiment remains mixed with 22 out of 31 brokers rating the stock a buy and a mean price target of $571, though Deutsche Bank is a seller at $366.
📉 Technical indicators show weakness with shares trading 15% below the 200-day moving average and an RSI of 44 providing no clear directional signal.
👥 Insider sentiment turned cautious recently as over 7,000 shares were sold by insiders over the past 90 days.
📅 The company is scheduled to report second-quarter results in July with analysts forecasting revenue of $2.82 billion.
Bullish Signals
Revenue grew 23% YoY to $2.77 billion.
EPS of $2.50 beat the $2.08 estimate.
Installed 431 new da Vinci systems this quarter.
Recurring revenue now forms the bulk of business.
Focus Partners Wealth stake rose nearly 42%.
Vanguard holding enlarged by 11.5% recently.
22 of 31 brokers rate the stock a buy.
Mean price target stands at $571.
Japan reimbursement expansion expected in June 2026.
Risk Factors
Shares down 25% since year start.
FDA warning requires surgical stapler recall.
Chinese rivals escalate competition in robotics.
OpenAI enters medical robotics as rival.
Insiders sold over 7,000 shares recently.
High volatility at 36% increases risk.
Deutsche Bank targets $366 bearish view.
RSI at 44 lacks upward technical support.
Bullish Signals
Intuitive Surgical delivered a standout first quarter with revenue growing 23% year-over-year to reach $2.77 billion.
Earnings per share of $2.50 significantly exceeded the analyst consensus estimate of $2.08, demonstrating strong profitability.
The company installed 431 new da Vinci systems in the quarter, indicating continued demand for its core product.
Recurring revenue now accounts for the bulk of the business, providing a stable and predictable cash flow foundation.
Major institutional investors like Focus Partners Wealth increased their stakes by nearly 42%, signaling confidence in long-term value.
Vanguard enlarged its holding by 11.5% and Sands Capital Management added 2.7% to its position, showing continued accumulation by large funds.
Analysts remain broadly bullish with 22 out of 31 brokers rating the stock a buy and a mean price target of $571.
Japan's upcoming June 2026 reimbursement expansion for seven new procedures offers a clear path to restoring growth momentum in that region.
Risk Factors
Shares have declined roughly 25% since the start of the year, trading significantly below their January peak of EUR 516.50.
The FDA issued a warning requiring the recall of specific surgical stapler models, posing an immediate regulatory and reputational risk.
Competition is escalating as Chinese manufacturers rapidly gain ground in the surgical robotics market.
OpenAI's recent move into robotics has stoked fears of a new, powerful rival entering the medical field.
Insider sentiment has turned cautious with more than 7,000 shares sold by insiders over the past 90 days.
The stock exhibits high volatility at 36%, keeping traders on edge and increasing short-term price instability.
Deutsche Bank stands alone as a seller with a price target of $366, reflecting significant bearish divergence from other analysts.
The Relative Strength Index sits at a neutral 44, providing no clear technical support for an immediate upward trend.
Intuitive Surgical (ISRG) reported a strong capital placement performance in the first quarter of 2026, placing 431 da Vinci systems, a 17% year-over-year increase. This growth is largely driven by the accelerating adoption of the da Vinci 5 platform, which accounted for 232 placements. However, analysis suggests a significant portion of this surge stems from an ongoing upgrade cycle where hospitals replace older systems with newer models featuring advanced capabilities like force feedback and digital integration.
Trade-in activity surged to 119 transactions in Q1 2026 compared to 67 the prior year, indicating existing customers are refreshing their fleets. Concurrently, leasing represented 56% of placements, up from 47% previously, reflecting a shift toward flexible capital spending models due to uncertain hospital budgets. Leasing revenues grew 28%, supported by higher utilization and a premium mix of da Vinci 5 systems.
Management argues that while the upgrade cycle may moderate, structural demand drivers remain robust, including 17% procedure growth, rising utilization, expanding international adoption, and recurring revenues now comprising 86% of total sales. The article also covers peers Globus Medical (GMED), which saw strong momentum in its Enabling Technologies segment, and Stereotaxis (STXS), which is rebuilding its business with the upcoming GenesisX platform.
Valuation-wise, ISRG shares have declined 27.5% year-to-date, trading at a forward P/E of 37.39, which is above the industry average but below its five-year median of 70.02. The Zacks Consensus Estimate for 2026 earnings implies a 16.5% rise from the prior year, and the stock currently carries a Zacks Rank #3 (Hold). The article concludes with promotional content regarding other Zacks investment reports.
📈 ISRG placed 431 da Vinci systems in Q1 2026, up 17% YoY.
🔄 Trade-in transactions jumped to 119 as hospitals upgrade older systems.
💰 Leasing accounted for 56% of placements, rising from 47%.
🏥 Recurring revenues now represent 86% of Intuitive Surgical's total sales.
📉 ISRG shares are down 27.5% YTD vs a 17.6% industry decline.
📈 ISRG placed 431 da Vinci systems in Q1 2026, up 17% year over year.
🔧 The da Vinci 5 platform drove 232 of the total placements during the quarter.
🔄 Trade-in transactions jumped to 119 from 67 a year ago as hospitals upgrade older systems.
💰 Leasing accounted for 56% of placements, rising from 47% in the prior quarter.
📊 Leasing revenues grew 28%, supported by higher utilization and premium system mix.
🏥 Recurring revenues now represent 86% of Intuitive Surgical's total sales.
🌍 Management cites structural demand drivers including 17% procedure growth and international expansion.
📉 ISRG shares are down 27.5% year-to-date compared to a 17.6% industry decline.
💵 The stock trades at a forward P/E of 37.39, below its five-year median of 70.02.
🎯 Zacks Consensus estimates 2026 earnings will rise 16.5% from the prior year.
🛠️ Peer Globus Medical (GMED) saw its Enabling Technologies segment grow 21.1% YoY.
🚀 Stereotaxis (STXS) expects to launch five active GenesisX programs in 2026.
Bullish Signals
ISRG capital placements rose 17% with 431 systems placed.
Da Vinci 5 gained traction with 232 quarter placements.
Trade-in transactions doubled to 119 transactions.
Leasing adoption accelerated to 56% of placements.
Recurring revenues reached 86% of total sales.
Risk Factors
Capital surge may be driven by upgrade cycle rather than new expansion.
Trade-in activity suggests placement growth could moderate once replacement normalizes.
Shares lost 27.5% so far this year, underperforming historical valuation metrics.
Forward P/E of 37.39 is above industry average despite below five-year median.
Bullish Signals
ISRG delivered a 17% year-over-year increase in capital placements, placing 431 systems in Q1 2026.
The da Vinci 5 platform is gaining traction with 232 placements in the quarter, signaling strong demand for new capabilities.
Trade-in activity doubled to 119 transactions, indicating robust replacement demand from existing hospital customers.
Leasing adoption accelerated to 56% of placements, providing hospitals with flexible capital models amid budget constraints.
Recurring revenues have reached 86% of total sales, highlighting a strong shift toward high-margin ecosystem growth.
Management points to structural drivers like 17% procedure growth and rising utilization supporting long-term demand.
Peer Globus Medical reported a 21.1% year-over-year growth in its Enabling Technologies segment.
Risk Factors
A significant portion of the capital placement surge may be driven by an upgrade cycle rather than pure new-market expansion.
Elevated trade-in activity suggests that current placement growth could moderate once the replacement cycle normalizes.
ISRG shares have lost 27.5% so far this year, underperforming relative to its historical valuation metrics.
The stock trades at a forward P/E of 37.39, which is above the industry average despite being below its five-year median.
Intuitive Surgical (ISRG) is pivoting its growth strategy from developing new robotic platforms to building a digital ecosystem around its existing installed base of da Vinci systems. During the first quarter of 2026, management outlined a long-term plan leveraging surgical data, artificial intelligence, and connected workflows to enhance patient outcomes and differentiate the franchise. The core of this strategy is a "data flywheel" where the da Vinci 5 platform captures comprehensive datasets including surgical video, robotic kinematic data, force-feedback information, and clinical context from electronic medical records. By combining these proprietary datasets, Intuitive aims to gain deeper insights into procedural variation, workflow efficiency, and patient outcomes, creating a competitive advantage that strengthens as procedure volumes and installed systems grow.
The initial wave of AI applications will focus on decision support and workflow optimization, featuring tools like anatomy identification, tissue-plane visualization, and guidance to assist surgeons during procedures. Beyond the operating room, these analytics are intended to help hospitals improve robotic program efficiency, utilization, and cost management. The company is also pursuing advanced capabilities such as augmented dexterity, camera automation, and surgical assistance, while reaffirming that telesurgery remains on its roadmap to support mentoring, proctoring, and remote collaboration among surgeons. With approximately 1,500 da Vinci 5 systems in the field and over three million annual procedures, Intuitive is generating a massive repository of surgical intelligence that competitors cannot easily replicate, creating a self-reinforcing advantage expected to enable better AI models and more differentiated products over the next three to five years.
From a valuation perspective, ISRG shares have lost 27.2% year-to-date compared with a 15.2% decline for the industry. The company trades at a forward price-to-earnings ratio of 37.65, which is above the industry average but lower than its five-year median of 70.02. It carries a Value Score of F and a Zacks Rank #3 (Hold). Analysts forecast a 16.5% rise in earnings for 2026 compared to the prior year. The article also contextualizes ISRG's strategy alongside peers like Abbott Laboratories and Boston Scientific, noting how they are similarly building technology moats through proprietary devices, digital health platforms, and integrated ecosystems to create switching costs and maintain leadership positions in high-growth medical device markets.
📈 ISRG shifts focus from new platforms to expanding its digital ecosystem around installed bases.
🤖 AI applications will enhance surgical outcomes via decision support and workflow optimization tools.
🛡️ Data from 1,500 systems creates a competitive moat against emerging rivals.
📉 Shares dropped 27.2% this year but trade at a forward P/E of 37.65.
🔬 Competitors like Abbott and Boston Scientific are also building proprietary technology ecosystems.
📈 Intuitive Surgical (ISRG) is shifting its growth strategy from new robotic platforms to building a digital ecosystem around its installed base.
🤖 The company's long-term strategy centers on leveraging surgical data, artificial intelligence, and connected workflows to enhance outcomes for the da Vinci franchise.
📊 A "data flywheel" approach captures video, kinematic data, force-feedback, and clinical context from connected electronic medical records via the da Vinci 5 platform.
🔒 Management believes proprietary datasets provide a unique competitive advantage that strengthens as procedure volumes and installed systems grow.
🧠 The first wave of AI applications will focus on decision support, anatomy identification, tissue-plane visualization, and workflow optimization tools.
🏥 Beyond the operating room, AI-driven analytics aim to help hospitals improve robotic program efficiency, utilization, and cost management.
🚀 Advanced capabilities under development include augmented dexterity, camera automation, and other forms of surgical assistance.
📡 Telesurgery remains on the roadmap, building on existing adoption of My Intuitive+ and telepresence tools for remote collaboration.
🛡️ The scale of data from approximately 1,500 da Vinci 5 systems and over three million annual procedures creates a competitive moat against emerging rivals.
📉 ISRG shares have lost 27.2% so far this year, outperforming the industry's 15.2% decline in terms of relative loss but still down significantly.
💰 Intuitive Surgical trades at a forward P/E ratio of 37.65, which is above the industry average but lower than its five-year median of 70.02.
📈 The Zacks Consensus Estimate for 2026 earnings implies a 16.5% rise from the year-ago period's level.
⚖️ The stock currently carries a Zacks Rank #3 (Hold) and a Value Score of F.
🔬 Abbott Laboratories and Boston Scientific are also building technology moats through proprietary devices, digital platforms, and integrated ecosystems in their respective markets.
Bullish Signals
da Vinci 5 captures comprehensive surgical data for a proprietary flywheel.
1,500 systems and 3M procedures build an unreplicable competitive moat.
AI tools optimize workflow with anatomy identification and tissue visualization.
My Intuitive+ telesurgery roadmap builds on growing remote collaboration adoption.
2026 earnings expected to rise 16.5% per Zacks Consensus Estimate.
Forward P/E of 37.65 is below five-year median of 70.02.
Risk Factors
ISRG shares lost 27.2% YTD despite outperforming industry decline.
Forward P/E ratio of 37.65 exceeds industry average.
Value Score F and Zacks Rank #3 signal neutral sentiment.
Bullish Signals
Intuitive Surgical's da Vinci 5 platform captures comprehensive surgical data including video, kinematic data, force-feedback, and clinical context, creating a powerful proprietary data flywheel.
With approximately 1,500 da Vinci 5 systems in the field and more than three million annual procedures, ISRG is generating real-world datasets that competitors cannot easily replicate to build a durable competitive moat.
The company's long-term strategy leverages AI for decision support and workflow optimization, including anatomy identification and tissue-plane visualization tools to assist surgeons during procedures.
Management reaffirmed that telesurgery remains on the roadmap, building on growing adoption of My Intuitive+ and telepresence tools for remote collaboration among surgeons.
Zacks Consensus Estimate for ISRG's 2026 earnings implies a 16.5% rise from the year-ago period's level, indicating strong growth expectations.
Despite trading at a forward P/E of 37.65, ISRG's valuation is still lower than its five-year median of 70.02, suggesting potential upside relative to historical norms.
Risk Factors
ISRG shares have lost 27.2% year-to-date, significantly outperforming the industry's 15.2% decline.
The company trades at a forward price-to-earnings ratio of 37.65, which is above the industry average.
Intuitive Surgical carries a Value Score of F and a Zacks Rank #3 (Hold), indicating neutral to negative sentiment from analysts.
Intuitive Surgical has promoted Taylor Patton to the role of Chief Commercial and Marketing Officer, effective July 1, succeeding Henry Charlton. Patton, a veteran executive with nearly two decades at the company, previously served as Global Senior Vice President of Endoluminal Business, where he led the launch of the Ion platform for lung biopsy procedures. In his new capacity, Patton will oversee global commercial operations and marketing strategies to support anticipated growth in an increasingly competitive robotic surgery market across the U.S., Europe, China, and other regions.
Henry Charlton is transitioning to Senior Vice President of Global Business Operations, where he will focus on customer support and value generation for patients and healthcare systems worldwide. CEO Dave Rosa highlighted Patton's track record in building commercial organizations and launching new technologies as key qualifications for the role. This leadership change aligns with Intuitive's strategic efforts to expand its global footprint despite a noted slowdown in growth for da Vinci procedures outside the U.S., though the company maintains a positive outlook for 2026 worldwide procedure growth driven by increased use of the system in general surgeries.
👤 Taylor Patton promoted to Chief Commercial and Marketing Officer effective July 1.
🔄 Henry Charlton moves to Senior Vice President of Global Business Operations.
📈 Raised 2026 growth outlook despite slower international procedure volume recently.
🤖 Patton joins executive team after nearly two decades launching key technologies.
🏢 Company expands commercial operations to prepare for anticipated global growth.
👤 Taylor Patton has been promoted to chief commercial and marketing officer at Intuitive Surgical.
📅 The promotion is effective as of July 1, succeeding Henry Charlton in the role.
🔄 Patton will move from his previous position as global senior vice president of endoluminal business.
🏢 He joins the executive leadership team after nearly two decades with the company.
🌍 His appointment comes as Intuitive faces increasing competition in robotic surgery markets globally.
📈 The company is expanding its commercial operations to prepare for anticipated global growth.
🗣️ CEO Dave Rosa praised Patton's ability to launch new technologies and build commercial organizations.
🤖 Patton previously led the launch of the Ion platform, used for lung biopsy procedures.
🔄 Henry Charlton will transition to senior vice president of global business operations.
🏥 Charlton's new role focuses on generating value for patients and ensuring world-class support globally.
📉 Growth in da Vinci robot procedures outside the U.S. has slowed compared to prior quarters.
🔍 However, greater use of the system in general surgeries has encouraged a raised 2026 growth outlook.
Bullish Signals
Intuitive appointed Taylor Patton as Chief Commercial and Marketing Officer.
Patton will lead global expansion after launching Ion platform previously.
CEO Dave Rosa expressed strong confidence in Patton's leadership trust.
Intuitive expands commercial operations for robotic surgery market growth.
Company raised 2026 da Vinci procedure growth outlook due to demand.
Risk Factors
Intuitive faces rising global competition from new entrants.
da Vinci growth slows outside U.S. despite strength.
Bullish Signals
Intuitive has appointed Taylor Patton as Chief Commercial and Marketing Officer, a veteran executive with nearly two decades of experience at the company.
Patton is uniquely positioned to lead Intuitive's global expansion, having previously led the launch of the Ion platform and built commercial organizations across multiple geographies.
CEO Dave Rosa stated that Patton has demonstrated the ability to earn trust with customers around the world, signaling strong confidence in his leadership capabilities.
Despite competition, Intuitive is expanding its commercial operations to prepare for continued global growth in robotic surgery markets.
The company raised its 2026 worldwide da Vinci procedure growth outlook due to greater use of the system in general surgeries, indicating sustained demand and market penetration.
Risk Factors
Intuitive faces increasing competition from a steady stream of new market entrants in the U.S., Europe, China, and other countries.
Growth in da Vinci robot procedures outside the U.S. has slowed from prior quarters, despite remaining strong.
Goldman Sachs maintained its Buy rating on Intuitive Surgical (ISRG) but lowered its price target from $621 to $558 as of May 27, 2026. The firm noted that the MedTech sector is experiencing one of its weakest periods in 15-20 years due to performance and valuation pressures, slower growth, reimbursement issues, competitive risks, and aging investment narratives. This adjustment follows a similar move by Bank of America on May 18, 2026, which reduced its price target from $650 to $520 while maintaining a Buy rating, citing a "new reality of medtech valuations" driven by fewer product cycles, ACA and utilization concerns, post-war inflation, and shifting capital flows toward data centers.
Despite the analyst downgrades, Intuitive Surgical reported strong financial results for the first quarter with adjusted EPS of $2.50, beating the consensus estimate of $2.11, and revenue of $2.77 billion, surpassing the expected $2.62 billion. Worldwide procedures grew approximately 17% year-over-year, with da Vinci surgical systems placements rising to 431 from 367 in the first quarter of 2025, and Ion endoluminal system placements increasing to 52 from 49 the previous year. The company continues to develop and market products supporting minimally invasive care globally.
📉 Goldman Sachs and Bank of America lowered ISRG price targets despite maintaining Buy ratings.
💰 Intuitive Surgical beat Q1 EPS and revenue estimates with strong procedure growth.
🤖 da Vinci placements rose 20% while Ion systems jumped 39% year-over-year.
⚠️ Analysts cite sector headwinds, valuation concerns, and shifting capital away from healthcare.
📉 Goldman Sachs lowered its price target on Intuitive Surgical (ISRG) to $558 from $621 while maintaining a Buy rating.
⚠️ The firm cited MedTech as being in one of its weakest periods in 15-20 years regarding performance, valuation, and outlook.
📉 Bank of America also lowered its price target on ISRG to $520 from $650 but kept a Buy rating after hosting 34 medtech companies.
🤖 BofA highlighted concerns about "data centers over healthcare" and noted fewer product cycles in the current year.
💰 Intuitive Surgical reported Q1 adjusted EPS of $2.50, beating the consensus estimate of $2.11.
📈 Revenue for the quarter totaled $2.77 billion, surpassing the consensus estimate of $2.62 billion.
🔬 Worldwide procedures across da Vinci and Ion systems grew approximately 17% year-over-year.
🤖 da Vinci procedures increased by about 16%, while Ion procedures saw a significant jump of approximately 39%.
🏥 The company placed 431 da Vinci surgical systems, up from 367 in the first quarter of 2025.
🔌 Placement of Ion endoluminal systems reached 52 units compared to 49 last year.
🏢 Intuitive Surgical develops and markets products supporting minimally invasive care in the US and internationally.
⚖️ Analysts note pressure from sector rotation, slower growth, reimbursement issues, competitive risks, and aging investment narratives.
📉 Inflation pressure post-war and ACA utilization worries are contributing to the challenging medtech valuation environment.
Bullish Signals
Goldman Sachs maintains Buy rating on ISRG.
Q1 adjusted EPS beat consensus at $2.50.
Revenue of $2.77B surpassed analyst expectations.
Worldwide procedures grew 17% year-over-year.
da Vinci placements rose to 431 units.
Risk Factors
Goldman Sachs cut Intuitive Surgical target from $621 to $558 due to weak MedTech valuations.
Bank of America lowered target from $650 to $520 citing fewer cycles and data center shifts.
Analysts warn competitive risks and reimbursement issues drive sector weakness.
Bullish Signals
Goldman Sachs maintained a Buy rating on Intuitive Surgical (ISRG), signaling continued institutional confidence despite sector headwinds.
Intuitive Surgical reported Q1 adjusted EPS of $2.50, which significantly beat the consensus estimate of $2.11.
Revenue totaled $2.77B in the quarter, surpassing analyst expectations of $2.62B.
Worldwide procedures across da Vinci and Ion grew approximately 17% year-over-year, demonstrating strong operational momentum.
da Vinci procedures increased by approximately 16%, while Ion procedures saw robust growth of approximately 39%.
The company placed 431 da Vinci surgical systems in the quarter, a notable increase from 367 units placed in the first quarter of 2025.
Ion endoluminal system placements reached 52 units, up from 49 last year, indicating expanding market penetration.
Risk Factors
Goldman Sachs lowered its price target on Intuitive Surgical from $621 to $558, citing that the MedTech sector is experiencing one of its weakest periods in 15-20 years due to valuation pressures and slower growth.
Bank of America reduced its price target from $650 to $520, highlighting concerns over fewer product cycles, ACA and utilization worries, post-war inflation pressure, and a shift in capital flows toward data centers rather than healthcare.
Analysts explicitly cited competitive risks and reimbursement issues as key factors contributing to the sector's weak performance and negative outlook revisions.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)